NovalGen Ltd.
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies (NCT04763083) | NovalGen Ltd. | 2021-05-14 |
Track NovalGen Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.